Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China.

ABSTRACT:

Background

Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged <12 years has not been fully documented. We evaluated the therapeutic efficacy and safety of omalizumab in Chinese CSU population across all age groups.

Objectives

To assess the efficacy and safety of omalizumab treatment against CSU in China.

Methods

This study was a retrospective and observational study, and the clinical data of CSU patients treated with omalizumab from October 2018 to August 2021 were collected and analyzed.

Results

We enrolled 235 patients in this study, and 54.0% (n = 127/235) of patients were female. All patients received at least three injections of omalizumab treatment, and the mean treatment

SUBMITTER: Wang A 

PROVIDER: S-EPMC9672950 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature